CAH Gains More Than 29% in 4 Months: Will the Uptrend Continue?

Cardinal Health gained 29.3% over four months after fiscal 2026 revenue rose 14% to $254 billion and operating earnings increased 30% to $3.6 billion; Q4 operating earnings rose 30% to $935 million. Specialty revenue surpassed $50 billion and grew 25%, while fiscal 2027 Pharmaceutical and Specialty Solutions profit is expected to rise 8-11% despite slower 3-5% Pharma revenue growth. Planned M&A is projected to add 2-3% to fiscal 2027 profit growth, but tariff, fuel and commodity-cost pressures and tougher comparisons following exceptional fiscal 2026 growth remain key risks.

Analysis

CAH's rerating now requires investors to underwrite a durable mix shift rather than simply another distribution earnings beat. The key sensitivity is whether specialty/MSO economics translate into incremental gross-profit dollars faster than corporate costs and integration spending; if they do, CAH can sustain a higher multiple, but a return to ordinary specialty growth would expose the stock's premium to its own history. Equity-based physician affiliations also create a longer-duration retention moat, but introduce execution, physician-compensation and healthcare-regulatory complexity that a pure distributor multiple does not capture.

Competitive intensity is likely to shift value from manufacturers and independent practices toward the distributors with oncology, multispecialty and practice-management capabilities. COR appears the cleaner relative beneficiary: its lower valuation leaves more room for specialty-driven multiple expansion, while CAH must prove that acquisitions and new platforms can offset increasingly difficult comparisons. MCK retains scale advantages, but its higher exposure to the same attractive profit pools means specialty-margin competition could limit all three companies' ability to retain upside from mix.

Near-term, the setup is less about revenue and more about guidance credibility: commodity, freight and tariff offsets can create small gross-margin misses with outsized EPS consequences in distribution. Over the next 1-3 months, any evidence that the medical-products profit outlook is drifting toward the low end, or that acquired growth is decelerating faster than organic specialty growth, should pressure CAH disproportionately after the rally. The contrarian case is that the market is underestimating the earnings durability of at-home care, nuclear medicine and healthcare logistics; confirmation would support a structural rerating over 6-18 months.

Key Decisions for Investors

• Do not add outright CAH after the recent rerating; maintain only a core position and require the next earnings release to validate specialty growth, consolidated gross-margin progression and medical-products profit delivery before adding. Falsification: a guidance cut or margin commentary implying input-cost pressure cannot be offset.
• Initiate a 3-6 month relative-value position: long COR / short CAH in equal dollar amounts. The thesis is valuation catch-up for COR versus CAH mean reversion if specialty growth normalizes; target 8-12% relative return, with a 5% relative stop if CAH raises full-year profit guidance or demonstrates accelerating organic specialty margins.
• Keep MCK as the preferred defensive long within the group for investors needing distributor exposure, but avoid pairing it against COR: both have credible specialty catalysts and the spread is more dependent on idiosyncratic contract timing than on a clean valuation dislocation.
• Set an event watch on CAH's next quarterly update for specialty organic growth, acquisition contribution, and medical-products profitability. A clean beat driven by organic margin expansion—not acquisition accounting—would invalidate the cautious stance and justify revisiting an outright long for a 6-12 month horizon.